133 related articles for article (PubMed ID: 1825477)
1. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA).
Fung PY; Longenecker BM
Cancer Res; 1991 Feb; 51(4):1170-6. PubMed ID: 1825477
[TBL] [Abstract][Full Text] [Related]
2. Induction of alpha-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice.
Singhal A; Fohn M; Hakomori S
Cancer Res; 1991 Mar; 51(5):1406-11. PubMed ID: 1997178
[TBL] [Abstract][Full Text] [Related]
3. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.
Henningsson CM; Selvaraj S; MacLean GD; Suresh MR; Noujaim AA; Longenecker BM
Cancer Immunol Immunother; 1987; 25(3):231-41. PubMed ID: 2445486
[TBL] [Abstract][Full Text] [Related]
4. Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice.
Sugihara I; Yoshida M; Shigenobu T; Takagi H; Maruyama K; Takeuchi N; Toda M; Inoue M; Nakada H
Cancer Res; 2006 Jun; 66(12):6175-82. PubMed ID: 16778191
[TBL] [Abstract][Full Text] [Related]
5. Isolation and partial characterization of an epiglycanin-like glycoprotein from a new non-strain-specific subline of TA3 murine mammary adenocarcinoma.
Codington JF; Cooper AG; Miller DK; Slayter HS; Brown MC; Silber C; Jeanloz RW
J Natl Cancer Inst; 1979 Jul; 63(1):153-61. PubMed ID: 286825
[TBL] [Abstract][Full Text] [Related]
6. Further studies on the relationship between allotransplantability and the presence of the cell surface glycoprotein epiglycanin in the TA3-MM mouse mammary carcinoma ascites cell.
Miller SC; Codington JF; Klein G
J Natl Cancer Inst; 1982 Jun; 68(6):981-8. PubMed ID: 6953278
[TBL] [Abstract][Full Text] [Related]
7. Loss of strain specificity of the TA3-St subline: evidence for the role of epiglycanin in mouse allogeneic tumor growth.
Cooper AG; Codington JF; Miller DK; Brown MC
J Natl Cancer Inst; 1979 Jul; 63(1):163-9. PubMed ID: 221714
[TBL] [Abstract][Full Text] [Related]
8. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate.
Fung PY; Madej M; Koganty RR; Longenecker BM
Cancer Res; 1990 Jul; 50(14):4308-14. PubMed ID: 2364387
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
Streilein JW; Niederkorn JY
J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
[TBL] [Abstract][Full Text] [Related]
10. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
11. The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction.
Kemperman H; Wijnands Y; Wesseling J; Niessen CM; Sonnenberg A; Roos E
J Cell Biol; 1994 Dec; 127(6 Pt 2):2071-80. PubMed ID: 7528749
[TBL] [Abstract][Full Text] [Related]
12. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
[TBL] [Abstract][Full Text] [Related]
13. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
Tomita S; Fujiwara H; Yamane Y; Sano S; Nakajima H; Izumi Y; Arai H; Kawanishi Y; Tsuchida T; Hamaoka T
Jpn J Cancer Res; 1986 Feb; 77(2):182-9. PubMed ID: 3082830
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunodetection of murine mammary adenocarcinoma (TA3/Ha) lung and liver metastases with radioiodinated PNA.
Shysh A; Eu SM; Noujaim AA; Suresh MR; Longenecker BM
Int J Cancer; 1985 Jan; 35(1):113-9. PubMed ID: 3967949
[TBL] [Abstract][Full Text] [Related]
15. Ligation of tumour-produced mucins to CD22 dramatically impairs splenic marginal zone B-cells.
Toda M; Hisano R; Yurugi H; Akita K; Maruyama K; Inoue M; Adachi T; Tsubata T; Nakada H
Biochem J; 2009 Feb; 417(3):673-83. PubMed ID: 18925876
[TBL] [Abstract][Full Text] [Related]
16. Relation of human blood-groups MN to cancer cell surface antigens and to receptors for oncogenic viruses.
Springer GF; Desai PR
Ann Clin Lab Sci; 1974; 4(4):294-8. PubMed ID: 4142544
[TBL] [Abstract][Full Text] [Related]
17. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
Apostolopoulos V; Xing PX; McKenzie IF
Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
[TBL] [Abstract][Full Text] [Related]
18. Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients.
Codington JF; Bhavanandan VP; Bloch KJ; Nikrui N; Ellard JV; Wang PS; Jeanloz RW
J Natl Cancer Inst; 1984 Nov; 73(5):1029-38. PubMed ID: 6208403
[TBL] [Abstract][Full Text] [Related]
19. Delayed-type hypersensitivity to allogeneic mouse epidermal cell antigens. III. Analysis of suppressor cells.
Ishii N; Kawaguchi H; Aoki I; Takahashi T; Okuda K; Nakajima H
Exp Clin Immunogenet; 1987; 4(1):48-55. PubMed ID: 2978839
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the effector cells mediating an "innocent bystander" cytotoxicity reaction induced by a syngeneic mammary adenocarcinoma in mice.
Paul RD; Padmanabhan R; Lopez DM
Cancer Res; 1984 Oct; 44(10):4480-6. PubMed ID: 6467207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
